IL273395A - Combined therapies for cancer treatment - Google Patents

Combined therapies for cancer treatment

Info

Publication number
IL273395A
IL273395A IL273395A IL27339520A IL273395A IL 273395 A IL273395 A IL 273395A IL 273395 A IL273395 A IL 273395A IL 27339520 A IL27339520 A IL 27339520A IL 273395 A IL273395 A IL 273395A
Authority
IL
Israel
Prior art keywords
treating cancer
combination therapies
therapies
combination
cancer
Prior art date
Application number
IL273395A
Other languages
English (en)
Hebrew (he)
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of IL273395A publication Critical patent/IL273395A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL273395A 2017-09-30 2020-03-18 Combined therapies for cancer treatment IL273395A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762566398P 2017-09-30 2017-09-30
US201762578298P 2017-10-27 2017-10-27
US201862654024P 2018-04-06 2018-04-06
PCT/US2018/053542 WO2019067978A1 (en) 2017-09-30 2018-09-28 POLYTHERAPIES FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
IL273395A true IL273395A (en) 2020-05-31

Family

ID=65903287

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273395A IL273395A (en) 2017-09-30 2020-03-18 Combined therapies for cancer treatment

Country Status (13)

Country Link
US (1) US11661453B2 (enExample)
EP (1) EP3697442A4 (enExample)
JP (2) JP2020536066A (enExample)
KR (1) KR20200086664A (enExample)
CN (1) CN111372607A (enExample)
AU (1) AU2018338901A1 (enExample)
BR (1) BR112020006286A2 (enExample)
CA (1) CA3076515A1 (enExample)
IL (1) IL273395A (enExample)
MA (1) MA50409A (enExample)
MX (1) MX2020003770A (enExample)
SG (1) SG11202002862RA (enExample)
WO (1) WO2019067978A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3666794A1 (en) * 2016-11-01 2020-06-17 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
CN110382545A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
MA48475A (fr) 2017-04-24 2020-03-04 Tesaro Inc Procédés de fabrication de niraparib
TWI879716B (zh) * 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
BR112020006039A2 (pt) 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
CA3076515A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. Combination therapies for treating cancer
MA50618A (fr) 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations
WO2020063964A1 (zh) * 2018-09-29 2020-04-02 广州燃石医学检验所有限公司 一种基于二代测序的通过血浆检测微卫星稳定状态和基因组变化的方法
WO2022076917A1 (en) * 2020-10-08 2022-04-14 Kumquat Biosciences Inc. Modulators of cell proliferation and uses thereof
CA3219248A1 (en) * 2021-05-18 2022-11-24 Hyun Ju Cha Parp inhibitor-resistant cancer therapeutic agent
CN113234160B (zh) * 2021-05-26 2022-05-27 广州爱思迈生物医药科技有限公司 一种抗pd-1抗体及其应用
WO2024259248A2 (en) * 2023-06-15 2024-12-19 Memorial Sloan-Kettering Cancer Center Methods for treating cancer patients with homologous recombination deficiency based on pathognomonic long molecule footprints of backup repair pathways
KR20250087969A (ko) 2023-12-08 2025-06-17 주식회사 이앤지테크 팝업댓글 플랫폼을 활용한 소상공인 업소안내 증강현실 시스템 및 그 구동방법

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2806454B2 (ja) 1988-01-19 1998-09-30 武田薬品工業株式会社 脈管形成阻止剤
ES2053890T3 (es) 1988-09-01 1994-08-01 Takeda Chemical Industries Ltd Agente inhibidor de la angiogenesis.
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US9707302B2 (en) * 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
JP4611441B2 (ja) 2006-04-03 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体
GEP20115337B (en) 2007-01-10 2011-11-25 St Di Ricerche Di Biologia Molecolare P Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
KR20100102609A (ko) 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
NZ586123A (en) 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
JP5468015B2 (ja) 2008-01-08 2014-04-09 アクセリア ファーマシューティカルズ 抗菌ペプチド系に対する作動薬
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010091140A1 (en) 2009-02-04 2010-08-12 Bipar Sciences, Inc. Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2011153383A1 (en) 2010-06-04 2011-12-08 Bipar Science, Inc. Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
WO2011160063A2 (en) 2010-06-18 2011-12-22 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
EP3406594A1 (en) 2012-12-07 2018-11-28 Merck Sharp & Dohme Corp. Biocatalytic transamination process
EP2928473B1 (en) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
WO2014138101A1 (en) 2013-03-04 2014-09-12 Board Of Regents, The University Of Texas System Gene signature to predict homologous recombination (hr) deficient cancer
AR095363A1 (es) 2013-03-15 2015-10-14 Genentech Inc Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
HRP20210122T1 (hr) 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
EP4023765A1 (en) 2013-12-09 2022-07-06 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
CN105917007A (zh) 2014-01-16 2016-08-31 克洛维斯肿瘤有限公司 Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途
AU2015210886A1 (en) * 2014-01-29 2016-09-01 Caris Mpi, Inc. Molecular profiling of immune modulators
WO2015184145A1 (en) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
US20150344968A1 (en) 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
SG10201909173PA (en) 2015-04-01 2019-11-28 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
KR20170138555A (ko) 2015-04-28 2017-12-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료
WO2016200835A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
HK1257216A1 (zh) 2015-08-20 2019-10-18 益普生生物制药有限公司 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法
CA3003422A1 (en) 2015-10-26 2017-05-04 Medivation Technologies Llc Treatment of small cell lung cancer with a parp inhibitor
EP4071174A1 (en) 2016-02-15 2022-10-12 AstraZeneca AB Methods comprising fixed intermittent dosing of cediranib
EP3478286B1 (en) 2016-06-29 2024-01-03 Tesaro, Inc. Methods of treating ovarian cancer
EP3519051B1 (en) 2016-09-27 2021-09-22 Beigene, Ltd. Treatment of cancers using combination comprising parp inhibitors
EP3666794A1 (en) 2016-11-01 2020-06-17 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
EP3689419A1 (en) 2016-11-01 2020-08-05 AnaptysBio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
CN110382545A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法
CN110382000A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗tim-3抗体治疗癌症的方法
EP3606523A1 (en) 2017-03-27 2020-02-12 Tesaro, Inc. Niraparib formulations
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
MA48475A (fr) 2017-04-24 2020-03-04 Tesaro Inc Procédés de fabrication de niraparib
NZ759517A (en) 2017-04-27 2025-02-28 Tesaro Inc Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
US20200129482A1 (en) 2017-06-26 2020-04-30 Abbvie Inc. Treatment of non-small cell lung cancer
BR112020006039A2 (pt) 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
CA3076515A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. Combination therapies for treating cancer
MA50618A (fr) 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations
KR20200105862A (ko) 2017-12-27 2020-09-09 테사로, 인코포레이티드 암을 치료하는 방법
KR20200118117A (ko) 2018-02-05 2020-10-14 테사로, 인코포레이티드 소아용 니라파립 제제 및 소아용 치료 방법
EA201992594A1 (ru) 2018-03-26 2020-03-20 Тесаро, Инк. Комбинированные терапии для лечения рака
US11970530B2 (en) 2020-08-13 2024-04-30 Astrazeneca Ab Methods of treating homologous recombination deficient cancer

Also Published As

Publication number Publication date
MA50409A (fr) 2020-08-26
CN111372607A (zh) 2020-07-03
EP3697442A1 (en) 2020-08-26
CA3076515A1 (en) 2019-04-04
AU2018338901A1 (en) 2020-05-07
WO2019067978A1 (en) 2019-04-04
JP2023076826A (ja) 2023-06-02
EP3697442A4 (en) 2021-07-07
SG11202002862RA (en) 2020-04-29
US20200299387A1 (en) 2020-09-24
JP2020536066A (ja) 2020-12-10
US11661453B2 (en) 2023-05-30
MX2020003770A (es) 2020-07-29
BR112020006286A2 (pt) 2020-10-20
KR20200086664A (ko) 2020-07-17

Similar Documents

Publication Publication Date Title
IL270720A (en) Combination of treatments for cancer treatment
IL273395A (en) Combined therapies for cancer treatment
IL290149A (en) Combined treatment for cancer
IL253573A0 (en) Combined therapies for the treatment of cancers
IL254705B (en) Combined treatment for cancer
IL255060A0 (en) Combined treatment for cancer
IL258580B (en) Combined therapy for the treatment of malignancies
SG11201708861VA (en) Methods for treating cancer
EP3180010A4 (en) Combination therapy for treating cancer
SG11201609770TA (en) Combination therapies for the treatment of cancer
EP3407978A4 (en) POLYTHERAPY FOR THE TREATMENT OF CANCER
IL258685B (en) Combined treatment for malignancy
IL258684A (en) Combined treatment for malignancy
EP3630196A4 (en) COMBINATION THERAPIES FOR TREATMENT OF CANCER
IL257073A (en) Combined therapies for cancer treatment
EP3193884A4 (en) Combination therapy for treating cancer
IL255022A0 (en) Cancer treatment methods
IL268416A (en) Pharmaceutical combinations for cancer treatment
IL270820A (en) Antisense therapies for cancer treatment
IL255018A0 (en) Cancer treatment methods
SG11202010528XA (en) Combinations for treating cancer
IL255016A0 (en) Cancer treatment methods
IL278921A (en) Combined treatments for cancer
GB201703907D0 (en) Novel therapies for cancer
ZA201900438B (en) Combination therapies for treating cancer